KIT and gastrointestinal stromal tumor: In adults, approximately 85% of GIST is at least partially driven by mutations in KIT or PDGFRA, a finding that led to the current imatinib- and sunitinib-based regimens used to treat most adult GIST (Demetri et al., 2002, 2006).